Acute Lung Injury Market 2026 Market Size And Growth Forecast: Key Trends To Watch
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Acute Lung Injury Market Poised To Hit $3.19 Billion By 2030 With A 4.2% CAGR
The acute lung injury market size has demonstrated consistent expansion in recent years. Forecasts indicate an increase from $2.59 billion in 2025 to $2.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.4%. The growth observed in prior periods can be attributed to the significant prevalence of pneumonia and lung injuries caused by trauma, restricted access to advanced ventilation systems, a rising consciousness around critical care, the implementation of standard fluid management protocols, and a dependence on treatments provided in hospitals.
The acute lung injury market is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach $3.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.2%. The projected growth during this period can be ascribed to several factors, including the creation of new pharmacotherapies for ALI, greater integration of AI in patient monitoring, the worldwide expansion of intensive care units, increasing uptake of personalized treatment plans, and advancements in minimally invasive ventilation technologies. Key trends anticipated during the forecast period encompass a global rise in the incidence of acute lung injury cases, enhanced adoption of mechanical ventilation technologies, an expanding application of pharmacotherapy and fluid management, an emphasis on tools for early diagnosis and monitoring, and the enlargement of hospital-based critical care facilities.
Get A Free Sample Report With In-Depth Market Insights:
Acute Lung Injury Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The increasing incidence of respiratory ailments is projected to drive the expansion of the acute lung injury market in the foreseeable future. Respiratory diseases encompass a spectrum of conditions that impact the lungs and other parts of the respiratory system, leading to breathing difficulties and compromised lung function. The escalating occurrence of these diseases can be attributed to factors such as heightened air pollution, smoking, sedentary lifestyles, aging populations, and the influence of viral infections. Respiratory conditions, including pneumonia, induce acute lung injury by initiating severe inflammation and damaging the alveoli, which results in impaired gas exchange and respiratory distress. For instance, in October 2024, the National Asthma Council, an Australia-based non-profit organization, reported that Australia experienced a total of 474 asthma-related deaths in 2023, consisting of 325 females and 149 males. This figure is nearly identical to the 473 asthma-related deaths recorded in 2022, demonstrating a consistent trend in asthma mortality over these two years. Hence, the rising prevalence of respiratory diseases is a significant driver for the growth of the acute lung injury market.
Acute Lung Injury Market Breakdown By Product Type And Application
The acute lung injury market covered in this report is segmented –
1) By Injury Type: Direct Injury, Indirect Injury
2) By Therapy: Mechanical Ventilation, Pharmacotherapy, Fluid Management, Other Therapies
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Direct Injury: Trauma-Induced Acute Lung Injury, Aspiration Pneumonitis, Pneumonia-Related Acute Lung Injury, Inhalation Injury
2) By Indirect Injury: Sepsis-Related Acute Lung Injury, Shock-Induced Acute Lung Injury, Acute Lung Injury Due To Blood Transfusion, Acute Lung Injury Associated With Pancreatitis
Acute Lung Injury Market Innovation Trends Shaping Future Development
Leading companies active in the acute lung injury treatment market are prioritizing the development of advanced solutions, such as recombinant human plasma gelsolin (rhu-pGSN), to address dysfunctional inflammation, manage crucial immune responses, and potentially better patient outcomes in severe lung injury. Recombinant human plasma gelsolin (rhu-pGSN) is derived from gelsolin, a deeply conserved protein vital for controlling immune dysregulation in acute respiratory distress syndrome (ARDS). For instance, in June 2025, BioAegis Therapeutics, a US-based biotech company, obtained Fast Track designation from the U.S. Food and Drug Administration (FDA) for its primary product candidate, rhu-pGSN, specifically for treating ARDS. This treatment offers numerous unique advantages, including rebalancing dysfunctional inflammation without suppressing immune function, regulating critical immune responses in the lungs, and potentially improving outcomes for patients with severe inflammatory lung injury.
Acute Lung Injury Market Company Landscape And Competitive Strategy
Major companies operating in the acute lung injury market are Medtronic plc, Baxter International Inc., GE Healthcare Technologies Inc., Drägerwerk AG & Co. KGaA, Getinge AB, Koninklijke Philips N.V., Hamilton Medical AG, Vyaire Medical Inc., Vapotherm Inc., GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Faron Pharmaceuticals Oy, Windtree Therapeutics Inc., Apeiron Biologics AG, ReAlta Life Sciences Inc., Vasomune Therapeutics Inc., MediciNova Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc.
View The Full Acute Lung Injury Market Report:
Acute Lung Injury Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the acute lung injury market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lung injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
